|DB00057||Indium In-111 satumomab pendetide||For diagnosis of extrahepatic malignant cancers|
|DB00089||Capromab pendetide||For diagnosis of prostate cancer and detection of intra-pelvic metastases.|
|DB00113||Technetium Tc-99m arcitumomab||For imaging colorectal tumors|
|DB09266||Technetium Tc-99m tilmanocept||Indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management [FDA Label].
Indicated with or without scintigraphic imaging for guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma [FDA Label]. |
|DB09398||Fluoride ion F-18||18F is used as a bone imaging agent to define areas of altered osteogenic activity. It has been indicated for back pain and otherwise unexplained bone pain, child abuse, abnormal radiographic or laboratory findings, osteomyelitis, trauma, inflammatory and degenerative arthritis, avascular necrosis. Osteonecrosis of the mandible, condylar hyperplasia, and metabolic bone disease are also among the indications for fluoride imaging. |
|DB09502||Fludeoxyglucose (18F)||The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism.
Fludeoxyglucose F 18 Injection is indicated in positron emission tomography (PET) imaging for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnoses of cancer. |
|DB13848||Fluorodopa (18F)||Not Available|
|DB06704||Iobenguane||Detection of primary and metastatic pheochromocytoma or neuroblastoma |
|DB11835||Indium In-111 pentetreotide||Not Available|
|DB13146||Fluciclovine (18F)||Fluciclovine is indicated as a detection agent for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.[A31388] The overexpression of L-type amino acid transporters such as LAT1 and LAT3 that mediate the uptake of essential amino acids has been extensively reported as a tumoral mechanism of cell growth.[A31389]|